Integration of radiology, pathology, & genomics for prediction of response to anti-PD-1 in NSCLC

Jia Luo, MD, Dana-Farber Cancer Institute, Boston, MA, discusses the development of a multimodal biomarker to predict immunotherapy response in patients with non–small cell lung cancer (NSCLC). A cohort of 247 patients who have received immunotherapy as well have complete…

Integration of radiology, pathology, & genomics for prediction of response to anti-PD-1 in NSCLC

Source

0
(0)

Jia Luo, MD, Dana-Farber Cancer Institute, Boston, MA, discusses the development of a multimodal biomarker to predict immunotherapy response in patients with non–small cell lung cancer (NSCLC). A cohort of 247 patients who have received immunotherapy as well have complete radiology, pathology, genomics, and clinical data was assessed and the multimodal model based on the aforementioned factors improved the prediction of therapy response. This interview took place at the American Society of Clinical Oncology (ASCO) 2022 Annual Meeting in Chicago, IL.

0 / 5. 0